Bluejay Diagnostics' doubles after expanding partnership for sepsis test

Bluejay Diagnostics

09/10/2025 12:11

** Bluejay Diagnostics' BJDX.O shares more than double to $4.72 in premarket trading

** Co says it has expanded its partnership with Japan's SanyoSeiko to help commercialize its new Symphony rapid testing platform for management of sepsis

** Sepsis is a life-threatening condition caused by the body's response to infection, according to NIH

** BJDX's Symphony platform aims to deliver results for IL-6, a protein tied to inflammation in sepsis, in about 20 minutes

** Symphony is still awaiting U.S. FDA clearance, co says

** Up to last close, stock down ~62% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com;))